Today: 21 May 2026
Browse Category

NASDAQ:TWLO 9 January 2026 - 1 May 2026

Twilio Stock Jumps 20% After AI Voice Demand: Why Investors Are Repricing TWLO

Twilio Stock Jumps 20% After AI Voice Demand: Why Investors Are Repricing TWLO

Twilio raised its 2026 revenue-growth forecast to 14%-15% after first-quarter sales and adjusted earnings topped estimates. Shares surged about 20% Friday, trading near $178.39. First-quarter revenue rose 20% to $1.407 billion, with adjusted earnings at $1.50 a share versus $1.27 expected. Voice revenue climbed 20%, driven by demand for AI-enabled products.
1 May 2026
···
Twilio stock steadies near $114 premarket as fresh 10-K shows profit swing, cash flow lift

Twilio stock steadies near $114 premarket as fresh 10-K shows profit swing, cash flow lift

Twilio reported 2025 net income of $33.8 million on $5.07 billion revenue in its annual 10-K, reversing a loss a year earlier. Shares hovered near $113.80 in premarket trading after closing Tuesday up 4.9%. The company listed 402,000 active customer accounts and $945.4 million in free cash flow. CFO Aidan Viggiano received 37,554 restricted stock units set to vest from March 2026.
25 February 2026
··
Twilio (TWLO) stock slips after-hours on 2026 outlook — what investors watch next

Twilio (TWLO) stock slips after-hours on 2026 outlook — what investors watch next

Twilio shares fell 2.2% to $107.95 in after-hours trading Thursday after the company posted a 14% revenue rise to $1.37 billion and forecast 2026 revenue growth of up to 12.5%. The results beat analyst estimates, but the stock is down 22.4% year-to-date. Twilio reported over 402,000 active customer accounts and $1.1 billion remaining on its buyback authorization. The company expects higher carrier fees to reduce gross margin in 2026.
13 February 2026
···

Stock Market Today

  • Thales (ENXTPA:HO) Shares Decline but DCF Model Indicates Undervaluation
    May 21, 2026, 1:56 AM EDT. Shares of Thales (ENXTPA:HO) have fallen 12.8% over the past month and are down 9.7% year on year, despite strong long-term returns of 79.2% and 203.0% over three and five years respectively. Recent sector-specific developments in aerospace and defense, alongside broader market sentiment, contribute to price volatility. A discounted cash flow (DCF) analysis estimates Thales's intrinsic value at around €306.76 per share, suggesting the current price of €229.50 trades at a 25.2% discount and that the stock is undervalued. The P/E ratio remains a key metric but further valuation aspects need evaluation, as Thales scores 4 out of 6 on Simply Wall St's valuation checks. Investors should consider these factors when assessing the stock's potential.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop